Emily L Newman1, Lucas Albrechet-Souza1, Peter M Andrew1, John G Auld1, Kelly C Burk1, Lara S Hwa1, Eric Y Zhang1, Joseph F DeBold1, Klaus A Miczek2,3. 1. Psychology Department, Tufts University, Bacon Hall, 530 Boston Avenue, Medford, MA, 02155, USA. 2. Psychology Department, Tufts University, Bacon Hall, 530 Boston Avenue, Medford, MA, 02155, USA. Klaus.Miczek@tufts.edu. 3. Department of Neuroscience, Sackler School of Graduate Biomedical Sciences, Boston, MA, 02111, USA. Klaus.Miczek@tufts.edu.
Abstract
RATIONALE: Episodic bouts of social stress can precede the initiation, escalation, or relapse to disordered alcohol intake. Social stress may engender neuroadaptations in the hypothalamic-pituitary-adrenal (HPA) axis and in extrahypothalamic stress circuitry to promote the escalation of alcohol intake. OBJECTIVES: We aimed to (1) confirm a pattern of escalated drinking in socially defeated mice and to (2) test drugs that target distinct aspects of the HPA axis and extrahypothalamic neural substrates for their effectiveness in reducing murine, stress-escalated drinking. METHODS: Male C57BL/6J (B6) mice were socially defeated by resident Swiss-derived males for ten consecutive days receiving 30 bites/day. Ten days after the final defeat, cohorts of B6 mice received continuous or intermittent access to 20% EtOH (w/v) and water. After 4 weeks of drinking, mice were injected with weekly, systemic doses of the CRF-R1 antagonist, CP376395; the glucocorticoid receptor antagonist, mifepristone; the 11-beta-hydroxylase inhibitor, metyrapone; or the 5-alpha-reductase inhibitor, finasteride. RESULTS: Prior to drug treatments, defeated mice reliably consumed more EtOH than non-defeated controls, and mice given alcohol intermittently consumed more EtOH than those with continuous access. CP376395 (17-30 mg/kg) reduced continuous, but not intermittent EtOH intake (g/kg) in socially defeated mice. Mifepristone (100 mg/kg), however, increased drinking by defeated mice with intermittent access to alcohol while reducing drinking during continuous access. When administered finasteride (100 mg/kg) or metyrapone (50 mg/kg), all mice reduced their EtOH intake while increasing their water consumption. CONCLUSIONS: Mice with a history of episodic social defeat stress were selectively sensitive to the effects of CRF-R1 antagonism, suggesting that CRF-R1 may be a potential target for treating alcohol use disorders in individuals who escalate their drinking after exposure to repeated bouts of psychosocial stress. Future studies will clarify how social defeat stress may alter the expression of extrahypothalamic CRF-R1 and glucocorticoid receptors.
RATIONALE: Episodic bouts of social stress can precede the initiation, escalation, or relapse to disordered alcohol intake. Social stress may engender neuroadaptations in the hypothalamic-pituitary-adrenal (HPA) axis and in extrahypothalamic stress circuitry to promote the escalation of alcohol intake. OBJECTIVES: We aimed to (1) confirm a pattern of escalated drinking in socially defeated mice and to (2) test drugs that target distinct aspects of the HPA axis and extrahypothalamic neural substrates for their effectiveness in reducing murine, stress-escalated drinking. METHODS: Male C57BL/6J (B6) mice were socially defeated by resident Swiss-derived males for ten consecutive days receiving 30 bites/day. Ten days after the final defeat, cohorts of B6 mice received continuous or intermittent access to 20% EtOH (w/v) and water. After 4 weeks of drinking, mice were injected with weekly, systemic doses of the CRF-R1 antagonist, CP376395; the glucocorticoid receptor antagonist, mifepristone; the 11-beta-hydroxylase inhibitor, metyrapone; or the 5-alpha-reductase inhibitor, finasteride. RESULTS: Prior to drug treatments, defeated mice reliably consumed more EtOH than non-defeated controls, and mice given alcohol intermittently consumed more EtOH than those with continuous access. CP376395 (17-30 mg/kg) reduced continuous, but not intermittent EtOH intake (g/kg) in socially defeated mice. Mifepristone (100 mg/kg), however, increased drinking by defeated mice with intermittent access to alcohol while reducing drinking during continuous access. When administered finasteride (100 mg/kg) or metyrapone (50 mg/kg), all mice reduced their EtOH intake while increasing their water consumption. CONCLUSIONS:Mice with a history of episodic social defeat stress were selectively sensitive to the effects of CRF-R1 antagonism, suggesting that CRF-R1 may be a potential target for treating alcohol use disorders in individuals who escalate their drinking after exposure to repeated bouts of psychosocial stress. Future studies will clarify how social defeat stress may alter the expression of extrahypothalamic CRF-R1 and glucocorticoid receptors.
Entities:
Keywords:
Alcohol; C57BL/6J mice; CP376395; CRF-R1; Finasteride; Glucocorticoids; Intermittent access to alcohol; Metyrapone; Mifepristone; Social defeat stress
Authors: Adam P Croft; Matthew J O'Callaghan; S G Shaw; Gerald Connolly; Catherine Jacquot; Hilary J Little Journal: Brain Res Date: 2008-08-13 Impact factor: 3.252
Authors: Andrea Cippitelli; Ruslan Damadzic; Erick Singley; Annika Thorsell; Roberto Ciccocioppo; Robert L Eskay; Markus Heilig Journal: Pharmacol Biochem Behav Date: 2011-10-20 Impact factor: 3.533
Authors: Leandro F Vendruscolo; David Estey; Vivian Goodell; Lauren G Macshane; Marian L Logrip; Joel E Schlosburg; M Adrienne McGinn; Eva R Zamora-Martinez; Joseph K Belanoff; Hazel J Hunt; Pietro P Sanna; Olivier George; George F Koob; Scott Edwards; Barbara J Mason Journal: J Clin Invest Date: 2015-06-29 Impact factor: 14.808
Authors: Alex L Deal; Caroline E Bass; Valentina P Grinevich; Osvaldo Delbono; Keith D Bonin; Jeff L Weiner; Evgeny A Budygin Journal: Neuroscience Date: 2020-07-21 Impact factor: 3.590
Authors: Yann S Mineur; Vernon Garcia-Rivas; Merrilee A Thomas; Alexa R Soares; Sherry A McKee; Marina R Picciotto Journal: Psychopharmacology (Berl) Date: 2022-03-31 Impact factor: 4.530
Authors: Sadie E Nennig; Hannah D Fulenwider; Jacob E Eskew; Kimberly E Whiting; Mallory R Cotton; Gabrielle E McGinty; Matthew G Solomon; Jesse R Schank Journal: Alcohol Clin Exp Res Date: 2020-02-03 Impact factor: 3.455
Authors: Sema G Quadir; Sean M Tanino; Christian D Rohl; James J Sahn; Emily J Yao; Luíza Dos Reis Cruz; Pietro Cottone; Stephen F Martin; Valentina Sabino Journal: Neuropharmacology Date: 2020-11-20 Impact factor: 5.250
Authors: Emily L Newman; Herbert E Covington; Michael Z Leonard; Kelly Burk; Klaus A Miczek Journal: Biol Psychiatry Date: 2021-06-01 Impact factor: 12.810